Abstract
Atypical neuroleptics have enriched our treatment programmes, especially in childhood and adolescent schizophrenia. This article reviews the use of atypical neuroleptics in children and adolescents with schizophrenic disorder. It considers the receptor binding profile and pharmacological properties, indications, side effects, clinical applications and trials of atypical neuroleptics in comparison to the classical neuroleptic haloperidol in adolescent schizophrenia. Special emphasis is placed on the most common atypical neuroleptics clozapine, olanzapine and risperidone since most studies are carried out with these compounds, especially with clozapine. More clinically controlled trials have to be conducted since only one was performed so far. The place of the atypical neuroleptics is discussed and further studies are necessary in order to differentiate the indications tested so far and to find out if the spectrum of indications can be broadened.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Abczynska M, Kazmirek Z, Syguda J, Terminska K (1995) Own experience (1989–1994) in the treatment of adolescent schizophrenic paranoid syndromes with Leponex produced by Sandoz Company. Psychiatria Polska 29: 79–85
Aravagiri M, Marder SR, Wirshing D, Wirshing WC (1998) Plasma concentrations of risperidone and its 9-hydroxy metabolite and their relationship to dose in schizophrenic patients: simultaneous determination by a high performance liquid chromatography with electrochemical detection. Pharmacopsychiatry 31: 102–109
Armenteros JL, Whitaker AH, Welikson M, Stedge DJ, Gorman J (1997) Risperidone in adolescents with schizophrenia: an open pilot study. Journal of the American Academy of Child & Adolescent Psychiatry 36: 694–700
Beasley CM, Tollefson GD, Tran P, Satterlee W, Sanger T, Holman S, The Olanzapine HGAD Study Group (1996) Olanzapine versus placebo and haloperidol; acute phase results of the North American double blind olanzapine trial. Neuropsychopharmacology 14: 111–123
Blanz B, Schmidt MH (1993) Clozapine for schizophrenia [letter; comment]. Journal of the American Academy of Child & Adolescent Psychiatry 32: 223–224
Bleeham T (1993) Leponex® — Clozaril® (Clozapine) — Literature Review. Basle, Switzerland: Sandoz Pharma Ltd.
Bondolfi G, Dufour H, Patris M, May JP, Billeter U, Eap CB, Baumann P (1998) Risperidone versus clozapine in treatment-resistant chronic schizophrenia: a randomized double-blind study. The Risperidone Study Group. American Journal of Psychiatry 155: 499–504
Carman J, Peuskens J, Vangeneugden A (1995) Risperidone in the treatment of negative symptoms of schizophrenia: a meta-analysis. International Clinical Psychopharmacology 10: 207–213
Cardoni AA (1995) Risperidone: review and assessment of its role in the treatment of schizophrenia. Annals of Pharmacotherapy 29: 610–618
Casey DE (1989) Clozapine; neuroleptic-induced ES and tardive dyskinesia. Psychopharmacology 99: 47–53
Catlow JT, Barton RD, Clemens M, Gillespie TA, Goodwin M, Swanson SP (1995) Analysis of olanzapine in human plasma utilizing reversed-phase high-performance liquid chromatography with electrochemical detection. Journal of Chromatography B: Biomedical Applications 668: 85–90
Clement HW, Fleischhaker C, Sudhop B, Schulz E, Remschmidt H (1998) HPLC-determination of olanzapine in serum samples of schizophrenic patients. Biological Chemistry 379SSS: 39
Coward DM (1992) General pharmacology of clozapine. British Journal of Psychiatry 160 (Suppl 17): 5–11
Degner D, Rüther E (1998) „Atypische” Neuroleptika in der Schizophreniebehandlung. Nervenheilkunde 17: 472–479
Ekblom B, Haggstrom JE (1974) Clozapine (Leponex) compared with chlorpromazine: A double-blind evaluation of pharmacological and clinical properties. Current Therapy Research 16: 945–957
Elliger T, Englert E, Freisleder FJ, Friedrich M, Gierow B, Holstein K, Linder M, Remschmidt H, Resch F, Schmidt MH, Schulz E, Trott GE and Warnke A (1994) Zur Behandlung schizophrener Psychosen des Kindes- und Jugendalters mit Clozapin (Leponex). Konsensus-Konferenz vom 4. März 1994. Zeitschrift für Kinder- und Jugendpsychiatrie 22: 325–327
Flynn SW, MacEwan GW, Altman S, Kopala LC, Fredrikson DH, Smith GN, Honer WG (1998) An open comparison of clozapine and risperidone in treatment-resistant schizophrenia. Pharmacopsychiatry 31: 25–9
Frazier JA, Gordon CT, McKenna K, Lenane MC, Jih D, Rapoport JL (1994) An open trial of clozapine in 11 adolescents with childhood-onset schizophrenia. Journal of the American Academy of Child & Adolescent Psychiatry 33: 658–663
Gardner DM (1997) Olanzapine. Child and Adolescent Psychopharmacology News 2: 1–5
Gordon CT, Frazier JA, McKenna K, Giedd J, Zametkin A, Zahn T, Hommer D, Hong W, Kaysen D, Albus KE et al. (1994) Childhood-onset schizophrenia: an NIMH study in progress. Schizophrenia Bulletin 20: 697–712
Kapur S, Zipursky R, Remington G, Jones C, McKay G, Houle S (1997) PET evidence that loxapine is an equipotent blocker of 5-HT2 and D2 receptors: implications for the therapeutics of schizophrenia. American Journal of Psychiatry 154: 1525–1529
Kimmel SE, Calabrese JR, Woyshville MJ, Meltzer HY (1994) Clozapine in treatment-refractory mood disorders. Journal of Clinical Psychiatry 55 (Suppl B): 91–93
Kornhuber J, Weller M (1994) Aktueller Stand der biochemischen Hypothesen zur Pathogenese der Schizophrenie. Nervenarzt. 65: 741–754
Kumra S, Frazier JA, Jacobsen LK, McKenna K, Gordon CT, Lenane MC, Hamburger SD, Smith AK, Albus KE, Alaghband-Rad J, Rapoport JL (1996) Childhood-onset schizophrenia. A doubleblind clozapine-haloperidol comparison. Archives of General Psychiatry 53: 1090–1097
Kumra S, Jacobsen LK, Lenane MC, Karp BI, Frazier JA, Smith AK, Bedwell J, Lee P, Malanga CJ, Hamburger SD, Rapoport JL (1998) Childhood-onset schizophrenia: an open-label study of olanzapine in adolescents. Journal of the American Academy of Child and Adolescent Psychiatry 37: 377–385
Levkovitch Y, Kaysar N, Kronnenberg Y, Hagai H, Gaoni B (1994) Clozapine for schizophrenia [letter]. Journal of the American Academy of Child & Adolescent Psychiatry 33: 431
Lykes WC, Cueva JE (1996) Risperidone in children with schizophrenia. Journal of the American Academy of Child and Adolescent Psychiatry 35: 405–406
Mandoki M (1994) Anti-aggressive effects of clozapine in children and adolescents [abstract]. Proceedings of the Annual Meeting, Society for Biological Psychiatry, Philadelphia. Biological Psychiatry 35 (suppl): 469
Mandoki M (1997) Olanzapine in the treatment of early onset schizophrenia in children and adolescents. Biological Psychiatry 41 (suppl 7S): S22
Marder SR, Maibach RC (1994) Risperidone in the treatment of schizophrenia. American Journal of Psychiatry 154: 825–835
Mattiuz E, Franklin R, Gillespie T, Murphy A, Bernstein J, Chiu A, Hotten T, Kassahun K (1997) Disposition and metabolism of olanzapine in mice, dogs, and rhesus monkeys. Drug Metabolism and Disposition 25: 573–583
Meltzer HY (1995) Role of serotonin in the action of atypical antipsychotic drugs. Clinical Neuroscience 3: 64–75
Mijnster MJ, Schotte A, Docter GJ, Voorn P (1998) Effects of risperidone and haloperidol on tachykinin and opioid precursor peptide mRNA levels in the caudateputamen and nucleus accumbens of the rat. Synapse 28: 302–312
Olesen OV (1998a) Therapeutic drug monitoring of clozapine treatment. Therapeutic threshold value for serum clozapine concentrations. Clinical Pharmacokinetics 34: 497–502
Olesen OV, Licht RW, Thomsen E, Bruun T, Viftrup JE, Linnet K (1998) Serum concentrations and side effects in psychiatric patients during risperidone therapy. Therapeutic Drug Monitoring 20: 380–384
Piscitelli SC, Frazier JA, McKenna K, Albus KE, Grothe DR, Gordon CT, Rapoport JL (1994) Plasma clozapine and haloperidol concentrations in adolescents with childhood-onset schizophrenia: association with response. Journal of Clinical Psychiatry 55 (9, suppl B): 94–97
Remington G (1997) Selecting a neuroleptic and the role of side effects. Child and Adolescent Psychopharmacology News 2: 1–5
Remschmidt H (1993) Schizophrenic psychoses in children and adolescents. Triangle 32: 15–24
Remschmidt H, Martin M, Hennighausen K, Schulz E (2000) Treatment, rehabilitation and prevention. In Remschmidt H (Ed) Schizophrenia in children and adolescents. Developmental and clinical perspectives. Cambridge University Press, Cambridge: in press
Remschmidt H, Schulz E, Martin M (1994a) An open trial of clozapine in thirtysix adolescents with schizophrenia. Journal of Child and Adolescent Psychopharmacology 4: 31–41
Remschmidt H, Schulz E, Martin M, Warnke A, Trott GE (1994) Childhoodonset schizophrenia: history of the concept and recent studies. Schizophrenia Bulletin 20: 727–745
Roth BL, Craigo SC, Choudhary MS, Uluer A, Monsma FJ Jr, Shen Y, Meltzer HY, Sibley DR (1994) Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors. Journal of Pharmacology and Experimental Therapeutics 268: 1403–1410
Sanyal S, Van Tol HH (1997) Review the role of dopamine D4 receptors in schizophrenia and antipsychotic action. Journal of Psychiatric Research 31: 219–232
Schmidt MH, Trott GE, Blanz B et al. (1989) Clozapine medication in adolescents. In: Stefanis CN, Rabavilas AD, Soldatos CR (eds) Psychiatry: A World Perspective, vol. 1. Proceedings of the 8th World Congress of Psychiatry, Athens, Greece; October 12–19; Amsterdam: Excerpta Medica, pp 1100–1104
Schulz E, Fleischhaker C, Remschmidt H (1995) Determination of clozapine and its major metabolites in serum samples of adolescent schizophrenic patients by high performance liquid chromatography. Data from a prospective clinical trial. Pharmacopsychiatry 28: 20–25
Schulz E, Fleischhaker C, Remschmidt H (1996) Correlated changes in symptoms and neurotransmitter indices during maintenance treatment with clozapine or conventional neuroleptics in adolescents and young adulthood schizophrenia. Journal of Child and Adolescent Psychopharmacology 6: 119–131
Schulz E, Fleischhaker C, Clement HW, Remschmidt H (1997) Blood biogenic amines during clozapine treatment of earlyonset schizophrenia. Journal of Neural Transmission 104: 1077–1089
Sedvall G, Pauli S, Farde L, Karlsson P, Nyberg S, Nordstrom AL (1995) Recent, developments in PET scan imaging of neuroreceptors in schizophrenia. Israel Journal of Psychiatry & Related Sciences 32: 22–29
Siefen G, Remschmidt H (1986) Results of treatment with clozapine in schizophrenic adolescents. Zeitschrift für Kinder- und Jugendpsychiatrie 14: 245–247
Stockton ME, Rasmussen K (1996) Electrophysiological effects of olanzapine, a novel atypical antipsychotic, on A9 and A10 dopamine neurons. Neuropsychopharmacology 14: 92–104
Suppes T, McElroy SL, Gilber J, Dessain EC, Cole JO (1992) Clozapine in the treatment of dysphoric mania. Biological Psychiatry 32: 270–280
Toren P, Laor N, Weizman A (1998) Use of atypical neuroleptics in child and adolescent psychiatry. Journal of Clinical Psychiatry 59: 644–656
Turetz M, Mozes T, Toren P, Chernauzan N, Yoran-Hegesh R, Mester R, Wittenberg N, Tyano S, Weizman A (1997) An open trial of clozapine in neuroleptic-resistant childhood-onset schizophrenia. British Journal of Psychiatry 170: 507–510
Van Rossum JM (1966) The significance of dopamine receptor blockade for the mechanism of action of neuroleptic drugs. Archives of International Pharmacodynamic Therapy 160: 492–494
Zhang GO, McKay G, Hubbard JW, Midha KK (1996) Application of electrospray mass spectrometry in the identification of intact glucoronide and sulphate conjugates of clozapine in rat. Xenobiotica 26: 541–550
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Remschmidt, H., Hennighausen, K., Heiset, P. et al. Atypical neuroleptics in child and adolescent psychiatry. European Child & Adolescent Psychiatry 9 (Suppl 1), S9–S19 (2000). https://doi.org/10.1007/s007870070015
Issue Date:
DOI: https://doi.org/10.1007/s007870070015